

4 July 2022

Use of Specified Biosimilar Drugs in Rheumatology and Dermatology

Question 1. How many patients were treated by your Trust (for any condition) in the last 3 months with the following drugs: Adalimumab (Amgevita), Adalimumab (Humira), Adalimumab (Hyrimoz), Adalimumab (Idacio), Adalimumab (Imraldi?)

Ophthalmology figures for last 3 months:

ADALIMUMAB (HUMIRA) 40 mg Pre-Filled Pen	27
ADALIMUMAB (IMRALDI) 40 mg Pre-Filled Pen	19
ADALIMUMAB (IMRALDI) 40 mg Pre-filled Syringe	1

Gastrointestinal figures for last 3 months:

ADALIMUMAB (HUMIRA) 40 mg Pre-Filled Pen	75
ADALIMUMAB (IMRALDI) 40 mg Pre-Filled Pen	330*
ADALIMUMAB (AMGEVITA) 40 mg Pre-filled Syringe	330*

*Combined total for Imraldi and Amgevita

Question 2. How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs: Adalimumab (Amgevita), Adalimumab (Humira), Adalimumab (Hyrimoz), Adalimumab (Idacio), Adalimumab (Imraldi?)

Adalimumab (Amgevita)	32
Adalimumab (Humira)	413
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	691

Question 3. How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs: Adalimumab (Amgevita), Adalimumab (Humira), Adalimumab (Hyrimoz), Adalimumab (Idacio), Adalimumab (Imraldi?)

Adalimumab (Amgevita)	53
Adalimumab (Humira)	46
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	108